Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

BACKGROUND: Angiogenesis, among other signaling pathways, plays a key-role in sarcoma biology. Regorafenib (RE) has recently been shown to be effective in imatinib and sunitinib-refractory GIST in a phase III trial. METHODS/DESIGN: We are conducting an international trial (France, Austria and German...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Brodowicz, Thomas, Liegl-Atzwager, Bernadette, Tresch, Emmanuelle, Taieb, Sophie, Kramar, Andrew, Gruenwald, Viktor, Vanseymortier, Marie, Clisant, Stéphanie, Blay, Jean-Yves, Le Cesne, Axel, Penel, Nicolas
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4369830/
https://ncbi.nlm.nih.gov/pubmed/25884155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1143-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars